Cascadian Therapeutics (Formally known as Oncothyreon)
2601 Fourth Avenue
231 articles with Cascadian Therapeutics (Formally known as Oncothyreon)
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Seattle Genetics expects to complete today the acquisition of Cascadian Therapeutics through a merger without a vote of Cascadian Therapeutics stockholders pursuant to Section 251(h) of the Delaware General Corporation Law.
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc. (NASDAQ:CASC) at a price of $10.00 per share net to the seller in cash, without interest, less any applicable withholding taxes (the “Offer”).
Seattle Genetics is paying $10 per share in cash for Cascadian.
A look at the accomplishments that occurred during the fourth quarter of 2017.
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From the European Medicines Agency
This removes the requirement for pediatric clinical studies to support tucatinib market authorization application for treatment of metastatic breast cancer in Europe.
This will become effective prior to U.S. market open on Monday, December 18, 2017.
Prolonged Progression-Free Survival Reinforces Cascadian Therapeutics' Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
Results from this analysis will be presented in a poster session at the 2017 San Antonio Breast Cancer Symposium on Friday, December 8, 2017 beginning at 5:00 p.m. CST.
Cash, cash equivalents and investments totaled $113.0 million as of September 30, 2017, compared to $62.8 million at December 31, 2016.
Management will host a conference call and live audio webcast to discuss the results and provide a general corporate update
Financial terms of the deal were not disclosed.
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted To Tucatinib For The Treatment Of HER2+ Metastatic Colorectal Cancer
Cascadian Therapeutics Release: Tucatinib Data In Multiple Tumor Types Presented At The European Society For Medical Oncology (ESMO) 2017 Congress
Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation From FDA For Treatment Of Breast Cancer Patients With Brain Metastases
Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled For Today At 8:30 A.M. ET